These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35506077)

  • 1. Plasma matrix metalloproteinase 2 is associated with severity and mortality in pulmonary arterial hypertension.
    Arvidsson M; Ahmed A; Säleby J; Hesselstrand R; Rådegran G
    Pulm Circ; 2022 Jan; 12(1):e12041. PubMed ID: 35506077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma insulin-like growth factor binding protein 1 in pulmonary arterial hypertension.
    Bouzina H; Hesselstrand R; Rådegran G
    Scand Cardiovasc J; 2021 Feb; 55(1):35-42. PubMed ID: 32597241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of matrix metalloproteinases in patients with pulmonary hypertension: data from a prospective study.
    Marc A; Pop C; Sitar-Taut AV; Budisan L; Berindan-Neagoe I; Pop D
    BMC Cardiovasc Disord; 2021 Dec; 21(1):607. PubMed ID: 34930125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simplified risk stratification for pulmonary arterial hypertension associated with connective tissue disease.
    Li X; Sun X; Huang Y; Wang Y; Yang X; Wang J; Zhang N; Gu L; Zhang M; Wang Q
    Clin Rheumatol; 2019 Dec; 38(12):3619-3626. PubMed ID: 31385084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma TRAIL and ANXA1 in diagnosis and prognostication of pulmonary arterial hypertension.
    Arvidsson M; Ahmed A; Säleby J; Ahmed S; Hesselstrand R; Rådegran G
    Pulm Circ; 2023 Jul; 13(3):e12269. PubMed ID: 37502145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of HDAC1 alleviates monocrotaline-induced pulmonary arterial remodeling through up-regulation of miR-34a.
    Li F; Wang D; Wang H; Chen L; Sun X; Wan Y
    Respir Res; 2021 Aug; 22(1):239. PubMed ID: 34465322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating collagen biomarkers as indicators of disease severity in pulmonary arterial hypertension.
    Safdar Z; Tamez E; Chan W; Arya B; Ge Y; Deswal A; Bozkurt B; Frost A; Entman M
    JACC Heart Fail; 2014 Aug; 2(4):412-21. PubMed ID: 25023820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Changes of MMP-2,9 and TIMP-1 expressions in rats with pulmonary arterial hypertension after captopril and losartan interventions].
    Wang XM; Zhou TF; Liu B; Wei L; Shi K; Zhao SS; Hua YM; Liu HM
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Mar; 40(2):255-9. PubMed ID: 19462901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed Venous Oxygen Saturation Is a Better Prognosticator Than Cardiac Index in Pulmonary Arterial Hypertension.
    Khirfan G; Almoushref A; Naal T; Abuhalimeh B; Dweik RA; Heresi GA; Tonelli AR
    Chest; 2020 Dec; 158(6):2546-2555. PubMed ID: 32629034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
    Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
    Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension.
    Arvidsson M; Ahmed A; Bouzina H; Rådegran G
    ESC Heart Fail; 2021 Apr; 8(2):1230-1243. PubMed ID: 33403810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Plasma Matrix Metalloproteinase and Tissue Inhibitors of Matrix Metalloproteinase Levels With Adverse Treatment Outcomes Among Patients With Pulmonary Tuberculosis.
    Kumar NP; Moideen K; Nancy A; Viswanathan V; Thiruvengadam K; Sivakumar S; Hissar S; Nair D; Banurekha VV; Kornfeld H; Babu S
    JAMA Netw Open; 2020 Dec; 3(12):e2027754. PubMed ID: 33258908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma adrenomedullin peptides and precursor levels in pulmonary arterial hypertension disease severity and risk stratification.
    Bouzina H; Rådegran G
    Pulm Circ; 2020; 10(3):2045894020931317. PubMed ID: 32595932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metalloproteinases and their inhibitors are associated with pulmonary arterial stiffness and ventricular function in pediatric pulmonary hypertension.
    Schäfer M; Ivy DD; Nguyen K; Boncella K; Frank BS; Morgan GJ; Miller-Reed K; Truong U; Colvin K; Yeager ME
    Am J Physiol Heart Circ Physiol; 2021 Jul; 321(1):H242-H252. PubMed ID: 34085841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension.
    Giannelli G; Iannone F; Marinosci F; Lapadula G; Antonaci S
    Curr Med Res Opin; 2005 Mar; 21(3):327-32. PubMed ID: 15811199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension.
    Lepetit H; Eddahibi S; Fadel E; Frisdal E; Munaut C; Noel A; Humbert M; Adnot S; D'Ortho MP; Lafuma C
    Eur Respir J; 2005 May; 25(5):834-42. PubMed ID: 15863640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ventricular remodeling and matrix metalloproteinase-1 and its tissue inhibitor of metalloproteinase-1 in serum in third trimester of pregnant women with cardiac disease.].
    Zhang ZL; Lin JH; Tao RQ
    Zhonghua Fu Chan Ke Za Zhi; 2009 Oct; 44(10):731-5. PubMed ID: 20078957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating levels of copeptin predict outcome in patients with pulmonary arterial hypertension.
    Nickel NP; Lichtinghagen R; Golpon H; Olsson KM; Brand K; Welte T; Hoeper MM
    Respir Res; 2013 Nov; 14(1):130. PubMed ID: 24251953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up.
    Xanthouli P; Koegler M; Marra AM; Benjamin N; Fischer L; Eichstaedt CA; Harutyunova S; Nagel C; Grünig E; Egenlauf B
    Respir Res; 2020 May; 21(1):127. PubMed ID: 32448256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher plasma fibroblast growth factor 23 levels are associated with a higher risk profile in pulmonary arterial hypertension.
    Bouzina H; Hesselstrand R; Rådegran G
    Pulm Circ; 2019; 9(4):2045894019895446. PubMed ID: 31908768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.